CYTEK BIOSCIENCES INC (CTKB)

US23285D1090 - Common Stock

5.2  +0.09 (+1.76%)

After market: 5.2 0 (0%)

Fundamental Rating

5

Taking everything into account, CTKB scores 5 out of 10 in our fundamental rating. CTKB was compared to 55 industry peers in the Life Sciences Tools & Services industry. CTKB has a great financial health rating, but its profitability evaluates not so good. CTKB is valied quite expensively at the moment, while it does show a decent growth rate.



3

1. Profitability

1.1 Basic Checks

CTKB had negative earnings in the past year.
CTKB had a positive operating cash flow in the past year.
In multiple years CTKB reported negative net income over the last 5 years.
In multiple years CTKB reported negative operating cash flow during the last 5 years.

1.2 Ratios

CTKB has a better Return On Assets (-3.63%) than 63.64% of its industry peers.
CTKB has a better Return On Equity (-4.51%) than 65.45% of its industry peers.
Industry RankSector Rank
ROA -3.63%
ROE -4.51%
ROIC N/A
ROA(3y)-0.65%
ROA(5y)-4.87%
ROE(3y)-0.83%
ROE(5y)-10.32%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With a decent Gross Margin value of 54.97%, CTKB is doing good in the industry, outperforming 70.91% of the companies in the same industry.
CTKB's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for CTKB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.97%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.58%
GM growth 5YN/A

8

2. Health

2.1 Basic Checks

CTKB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CTKB has been reduced compared to 1 year ago.
CTKB has a better debt/assets ratio than last year.

2.2 Solvency

CTKB has an Altman-Z score of 5.19. This indicates that CTKB is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.19, CTKB is in the better half of the industry, outperforming 78.18% of the companies in the same industry.
The Debt to FCF ratio of CTKB is 0.31, which is an excellent value as it means it would take CTKB, only 0.31 years of fcf income to pay off all of its debts.
CTKB has a Debt to FCF ratio of 0.31. This is amongst the best in the industry. CTKB outperforms 92.73% of its industry peers.
CTKB has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
CTKB has a better Debt to Equity ratio (0.00) than 74.55% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.31
Altman-Z 5.19
ROIC/WACCN/A
WACC10.16%

2.3 Liquidity

CTKB has a Current Ratio of 7.33. This indicates that CTKB is financially healthy and has no problem in meeting its short term obligations.
CTKB has a better Current ratio (7.33) than 81.82% of its industry peers.
A Quick Ratio of 6.38 indicates that CTKB has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.38, CTKB belongs to the top of the industry, outperforming 81.82% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.33
Quick Ratio 6.38

6

3. Growth

3.1 Past

The earnings per share for CTKB have decreased strongly by -182.73% in the last year.
CTKB shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.59%.
CTKB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 27.65% yearly.
EPS 1Y (TTM)-182.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-900%
Revenue 1Y (TTM)12.59%
Revenue growth 3Y27.65%
Revenue growth 5YN/A
Sales Q2Q%-6.19%

3.2 Future

CTKB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.78% yearly.
CTKB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.39% yearly.
EPS Next Y-279.02%
EPS Next 2Y-26.43%
EPS Next 3Y24.78%
EPS Next 5YN/A
Revenue Next Year6.82%
Revenue Next 2Y11.02%
Revenue Next 3Y11.39%
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

2

4. Valuation

4.1 Price/Earnings Ratio

CTKB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 196.08, the valuation of CTKB can be described as expensive.
CTKB's Price/Forward Earnings is on the same level as the industry average.
The average S&P500 Price/Forward Earnings ratio is at 23.28. CTKB is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 196.08

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, CTKB is valued a bit cheaper than 65.45% of the companies in the same industry.
Industry RankSector Rank
P/FCF 64.2
EV/EBITDA N/A

4.3 Compensation for Growth

CTKB's earnings are expected to grow with 24.78% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.43%
EPS Next 3Y24.78%

0

5. Dividend

5.1 Amount

CTKB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

CYTEK BIOSCIENCES INC

NASDAQ:CTKB (11/4/2024, 8:02:03 PM)

After market: 5.2 0 (0%)

5.2

+0.09 (+1.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap683.85M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 196.08
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.63%
ROE -4.51%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 54.97%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 7.33
Quick Ratio 6.38
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-182.73%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-279.02%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)12.59%
Revenue growth 3Y27.65%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y